Mineralys Therapeutics Inc. has announced the successful achievement of statistical significance in its Explore-CKD Phase 2 trial, which focused on reducing systolic blood pressure and urinary albumin-to-creatinine ratio (UACR) while demonstrating a favorable safety profile. The company also continues its Explore-OSA Phase 2 trial involving participants with obstructive sleep apnea (OSA) and hypertension, with topline results anticipated in the first half of 2026. Additionally, Mineralys has presented positive results from its Launch-HTN and Advance-HTN pivotal trials at scientific meetings and published them in JAMA and NEJM. The company is preparing for a pre-NDA meeting with the FDA, scheduled for the fourth quarter of 2025, as part of its strategy to advance the development of lorundrostat for treating hypertension and related conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.